BioCentury
ARTICLE | Clinical News

Matrix reports Phase II data

October 12, 2000 7:00 AM UTC

In a Phase II study of 31 patients with unresectable liver metastases from colorectal cancer, MATX said that 9 patients responded to therapy with its IntraDose injectable gel containing cisplatin and ...